This map shows the geographic impact of S. Saks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Saks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Saks more than expected).
This network shows the impact of papers produced by S. Saks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Saks. The network helps show where S. Saks may publish in the future.
Co-authorship network of co-authors of S. Saks
This figure shows the co-authorship network connecting the top 25 collaborators of S. Saks.
A scholar is included among the top collaborators of S. Saks based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with S. Saks. S. Saks is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Saks, S. & Michael G. Rosenblum. (1992). Recombinant human TNF-alpha: preclinical studies and results from early clinical trials.. PubMed. 56. 567–87.34 indexed citations
Fendly, B M, Claire E. Kotts, Doris Vetterlein, et al.. (1990). The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer.. PubMed. 9(5). 449–55.39 indexed citations
Abbruzzese, James L., Bernard Levin, Jaffer A. Ajani, et al.. (1990). A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity.. PubMed. 9(5). 522–7.16 indexed citations
Aboulafia, David M., Steven A. Miles, S. Saks, & Ronald T. Mitsuyasu. (1989). Intravenous recombinant tumor necrosis factor in the treatment of AIDS-related Kaposi's sarcoma.. PubMed. 2(1). 54–8.43 indexed citations
10.
Ajani, Jaffer A., Adan Rios, James L. Abbruzzese, et al.. (1989). Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.. PubMed. 8(2). 140–6.14 indexed citations
11.
Abbruzzese, James L., Bernard Levin, Jaffer A. Ajani, et al.. (1989). Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.. PubMed. 49(14). 4057–61.58 indexed citations
12.
Jacobs, Charlotte, et al.. (1989). Recombinant interferon-gamma in the treatment of recurrent nasopharyngeal carcinoma.. PubMed. 8(3). 221–6.7 indexed citations
Quesada, Jorge R., Lydia M. Evans, S. Saks, & Jordan U. Gutterman. (1988). Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.. PubMed. 7(3). 234–9.22 indexed citations
Benz, Christopher C., Michael W. DeGregorio, S. Saks, et al.. (1985). Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.. PubMed. 45(7). 3354–8.17 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.